

# PEDONCOVID - SFCE national cohort on SARS-CoV-2 (COVID-19) infections in paediatric oncology-haematology

Head :ROUGER-GAUDICHON Jérémie

Last update : 05/05/2021 | Version : 1 | ID : 73865

## General

### Identification

Detailed name SFCE national cohort on SARS-CoV-2 (COVID-19) infections in paediatric oncology-haematology

Sign or acronym PEDONCOVID

### General Aspects

Medical area Pediatrics

Study in connection with Covid-19 Yes

Pathology (details) Paediatric oncology

Keywords cancer; paediatrics; chemotherapy; SARS-CoV-2; COVID-19

### Scientific investigator(s) (Contact)

Name of the director ROUGER-GAUDICHON

Surname Jérémie

Organization CHU Caen Normandie

### Collaborations

### Funding

### Governance of the database

Sponsor(s) or organisation(s) responsible CHU Caen Normandie

Organisation status Public

### Additional contact

## Main features

## Type of database

Type of database	Study databases
Study databases (details)	Cohort study
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No

## Database objective

Main objective	Describe the presentation and clinical course of SARS-CoV-2 infection among patients followed up in a paediatric oncology-haematology department or young adult and adolescent unit at an SFCE centre, for cancer or a benign tumour treated with chemotherapy, radiotherapy or targeted therapy.
----------------	---

Inclusion criteria	<p>Children and legal representatives, or adult patients having received information on the study AND</p> <ul style="list-style-type: none"><li>- Patient followed up in a paediatric oncology-haematology department or young adult and adolescent unit at an SFCE centre for cancer or a benign tumour treated with chemotherapy, radiotherapy or targeted therapy, with a cancer treatment either ongoing or completed within the past 6 months, or a history of allogeneic haematopoietic stem cell transplantation with immunosuppressant therapy ongoing or discontinued within the past 6 months, or a history of CAR-T cell therapy</li></ul> <p>AND</p> <ul style="list-style-type: none"><li>- Diagnosis of SARS-CoV-2 infection confirmed by PCR or positive IgM serology</li></ul> <p>OR</p> <ul style="list-style-type: none"><li>- Clinical and radiological diagnosis characteristic of SARS-CoV-2 infection without confirmation of infection by PCR or positive IgM serology with:<ul style="list-style-type: none"><li>o Presence of at least 2 of the following signs in the event of contact with a subject currently presenting SARS-CoV-2 positive infection, or 3 of the following signs in the absence of contact: fever, cough, dysgeusia, dysosmia, myalgia, chest pain, dyspnoea, signs of respiratory distress, rhinorrhoea or nasopharyngeal congestion, diarrhoea, headaches, recent onset or exacerbation of asthenia and rash.</li></ul></li></ul> <p>AND</p>
--------------------	---

o One or more radiological abnormalities observed on chest CT scan compatible with a diagnosis of COVID-19: peripheral and/or subpleural and/or bilateral ground-glass opacities, intralobular thickening with a “crazy-paving” appearance, linear condensations with or without peripheral halo (reverse halo sign).

## Population type

Age  
Newborns (birth to 28 days)  
Infant (28 days to 2 years)  
Early childhood (2 to 5 years)  
Childhood (6 to 13 years)  
Adolescence (13 to 18 years)

Population covered Sick population

Pathology II - Neoplasms

Gender  
Male  
Woman

Geography area National

## Data collection

Dates

Size of the database

Size of the database (number of individuals) < 500 individuals

## Data

Database activity Current data collection

Type of data collected  
Clinical data  
Biological data

Clinical data (detail) Direct physical measures

Presence of a biobank No

## Procedures

Followed pathology

## Promotion and access

Promotion

